Low Mortality Rates For Sapien Valve, According To Edwards Lifesciences
Considering I’m fascinated with technology, it’s natural and logical that I would monitor the ongoing roll-out and clinical trials specific to the Sapien heart valve replacement device developed by Edwards Lifesciences.
The wonderful possibilities of this unique technology could help many, many, many aortic valve replacement patients in the future. The Sapien system (shown below) is less invasive and provides patients with a faster recovery.
Sapien Heart Valve Replacement Device
On that note, Edwards - the largest heart valve manufacturer on the planet - just released data from its first post-market study. The recent study showed that the Edwards SAPIEN valve had a low 30-day mortality, according to the company.
The data presented showed a 30-day survival rate of 93.7% in transfemoral procedures, and 89.7% in transapical procedures. These results were better than the predicted surgical survival in this high-risk patient cohort.
As always, I’ll continue to track the results of the Sapien device as its journey for FDA approval here in the United States continues.
Keep on tickin!
- Previous: “Did Your Heart Pound Like Crazy After Valve Surgery?” Asks Josh
- Next: "Did Robin Williams Have Open Heart Surgery Or Minimally Invasive Surgery?" Asks Marianna
Email Friend
Leave Comment
Print
Subscribe
